Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,461 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06639256RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial is testing a new drug called HY07121 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
JinanAges 18–80 - NCT04999384RecruitingPhase 1
First-in-human dose study for advanced cancers using AN4005
This early study tests AN4005 in adults with advanced or hard-to-treat solid tumors or certain lymphomas. The goal is to find a safe dose and see how the treatment behaves in the body.
Hackensack, New JerseyAges 18 years+ - NCT06947811RecruitingPhase 1/Phase 2
Almonertinib plus Palbociclib for KRAS-mutated solid tumors
This trial tests a combination of two targeted drugs, Almonertinib and Palbociclib, for people with advanced solid tumors that have a KRAS mutation. It aims to see if this new combination can shrink tumors or slow their growth, and it may be an option if your cancer has not responded to other treatments.
Guangzhou, GuangdongAges 18–70 - NCT07172919RecruitingPhase 2
Continued treatment with sotorasib for KRAS G12C cancer
This study is for people who are already taking the targeted therapy sotorasib (with or without another drug called panitumumab) in an Amgen clinical trial and are still doing well. It lets you keep receiving the same treatment after your original study ends, so you don't have to stop a medicine that is working for you.
Fort Myers, FloridaAges 18 years+ - NCT06832982RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03707808RecruitingPhase 1/Phase 2
Study drugs into a tumor plus immune therapy for advanced cancer
This trial tests injecting an immune-boosting mixture directly into a skin or lymph node tumor, along with immune-checkpoint medicines given through the vein. It aims to help the body recognize and fight advanced cancers that can’t be fully removed by surgery.
Jette, BrabantAges 18 years+ - NCT06805461Recruiting
Study of targeted chemotherapy for solid tumors
This trial is collecting information from people with solid tumors who receive a special type of chemotherapy delivered directly to the tumor. By tracking your health data over time, researchers hope to learn more about how well this approach works.
Coral Gables, FloridaAges 18 years+ - NCT05667194RecruitingPhase 1
Early study of KH617 for advanced brain and solid tumors
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06220838RecruitingPhase 1
Study of SC-101 for advanced solid tumors
This trial tests a new drug called SC-101 in people with advanced solid tumors that have not responded to other treatments. It may be an option if your tumor shows a specific protein called Nectin-4, which the drug targets.
Beijing, Beijing MunicipalityAges 18–80 - NCT06824155RecruitingEarly Phase 1
Radioactive drug for HER2-positive advanced cancers
This trial tests a radioactive drug (lutetium-177) that targets the HER2 protein, which is found on some cancer cells. It's for people with advanced, HER2-positive or HER2-low solid tumors that haven't responded to other treatments.
Kingswood, New South WalesAges 18 years+ - NCT07664150RecruitingPhase 1/Phase 2
Testing a new drug for HER2-positive cancers after other treatments stop working
This trial tests a new drug, CAN016, for people with advanced solid tumors that have HER2 expression or a HER2 gene change. You may qualify if your cancer has gotten worse after trying other HER2-targeted treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07505771RecruitingEarly Phase 1
A study of 177Lu-IM-3050 for advanced solid tumors
This trial tests a new treatment called 177Lu-IM-3050 for people with advanced solid tumors that have not responded to or stopped working with standard treatments. The treatment targets a protein called FAP found on some cancer cells and may help shrink tumors or slow their growth.
Palo Alto, CaliforniaAges 18 years+ - NCT06380309RecruitingEarly Phase 1
Study of experimental drug IDOV-SAFE for advanced digestive cancers
This trial tests an investigational drug for people with advanced digestive system cancers (like colorectal, stomach, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the drug is safe and helps control the cancer.
BeijingAges 18–75 - NCT06640413RecruitingPhase 1
Study of radioactive treatment for FAP-positive advanced tumors
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
Bergamo, BergamoAges 18 years+ - NCT06506643RecruitingPhase 1/Phase 2
Study of KLS-1 for solid tumors and CLL
This trial tests a new drug called KLS-1 for people with solid tumors (like melanoma, pancreatic, or prostate cancer) or chronic lymphocytic leukemia (CLL) that is no longer responding to standard treatments. The goal is to see if KLS-1 is safe and can shrink tumors or slow the cancer.
KropyvnytskyiAges 18 years+ - NCT07600749RecruitingPhase 1
MK-4884 study for advanced solid tumors
This early-stage study tests a new drug called MK-4884 in patients with advanced cancers that have spread. The trial includes colorectal, kidney, lung, and bile duct cancers, and aims to find the right dose and see if the drug helps shrink tumors.
San Antonio, TexasAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Phoenix, ArizonaAges 18 years+ - NCT07030712RecruitingPhase 1
Study of MK-8294 for advanced solid tumors
This trial tests an experimental drug called MK-8294 for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have certain types of cancer and are looking for a new treatment.
Chicago, IllinoisAges 18 years+ - NCT06979596RecruitingPhase 2
A study of MK-5684 for certain solid tumors
This trial tests an investigational drug called MK-5684 for people with specific types of breast, ovarian, or endometrial cancer. It aims to see if this treatment can help shrink or control the cancer when standard treatments have stopped working or are no longer effective.
Anchorage, AlaskaAges 18 years+ - NCT03093909RecruitingPhase 1
Breathing treatment with gemcitabine for lung cancer spread
This early-stage trial studies an inhaled (aerosol) form of gemcitabine to treat solid tumors that have spread to the lungs. It aims to see whether this lung-focused treatment is safe and how well it might work when standard curative options are not available.
Houston, TexasAges 12–50 - NCT03715933RecruitingPhase 1
Test drug INBRX-109 for advanced or metastatic solid tumors
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
Scottsdale, ArizonaAges 12–85 - NCT04390737RecruitingPhase 1/Phase 2
Study drug HH2853 for hard-to-treat lymphoma and solid cancers
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT04513444RecruitingPhase 2
Medical hypnosis to reduce anxiety during cancer radiotherapy
This Phase 2 study tests whether medical hypnosis can help people feel less anxious while they receive radiation treatment for cancer. It targets adults who have moderate to very high anxiety right after treatment planning.
ToulouseAges 18 years+ - NCT04684459RecruitingEarly Phase 1
CAR-T therapy for tumors with HER2 and PD-L1 markers
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Chengdu, SichuanAges 18–75
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,461 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.